Cyclophosphamide and Hydrocele - a phase IV clinical study of FDA data

Summary:

Hydrocele is reported as a side effect among people who take Cyclophosphamide (cyclophosphamide), especially for people who are 20-29 old, have been taking the drug for < 1 month also take Cosmegen, and have Rhabdomyosarcoma.

The phase IV clinical study analyzes which people have Hydrocele when taking Cyclophosphamide. It is created by eHealthMe based on reports of 185,094 people who have side effects when taking Cyclophosphamide from the FDA, and is updated regularly.

What is Cyclophosphamide?

Cyclophosphamide has active ingredients of cyclophosphamide. It is often used in multiple myeloma. eHealthMe is studying from 185,240 Cyclophosphamide users. Check the latest studies of Cyclophosphamide.

What is Hydrocele?

Hydrocele is found to be associated with 275 drugs and 388 conditions by eHealthMe. Check the latest studies of Hydrocele.

On Jul, 19, 2026

185,094 people reported to have side effects when taking Cyclophosphamide.
Among them, 16 people (0.01%) have Hydrocele.

Among these 16 people:

How long have people been on Cyclophosphamide when they have Hydrocele? *

What is the age of people who have Hydrocele when taking Cyclophosphamide? *

What are other drugs people take besides Cyclophosphamide? *

What are other side effects people have besides Hydrocele? *

Abdominal Neoplasm (cancer of the stomach): 8 people, 50.00%
Urethral Stenosis (narrowing of the urethra, may cause decreased urine output): 8 people, 50.00%
Focal Nodular Hyperplasia (tumour of the liver): 8 people, 50.00%
Second Primary Malignancy (after getting cure a cancer, a new cancer development): 6 people, 37.50%
Hernia (hernia happens when part of an internal organ or tissue bulges through a weak area of muscle): 4 people, 25.00%
Premature Baby: 4 people, 25.00%
Respiratory Distress Syndrome (Rds) In Infants (respiratory disease of newborn babies, especially premature babies, characterized by distressful breathing, cyanosis, and the formation of a glassy membrane over the alveoli of the lungs): 4 people, 25.00%
Blood Creatinine Increased: 3 people, 18.75%
Mitral Valve Incompetence (inefficient heart valve): 3 people, 18.75%
Joint Contracture (a permanent shortening of a muscle or joint): 3 people, 18.75%

What are the existing conditions these people have? *

Rhabdomyosarcoma (cancer of the bone, soft tissues, or connective tissue (e.g., tendon or cartilage)): 8 people, 50.00%
High Blood Pressure: 3 people, 18.75%
Systemic Lupus Erythematosus (an autoimmune disease, which means the body's immune system mistakenly, attacks healthy tissue): 2 people, 12.50%
Non-Hodgkin's Lymphoma (malignant (cancer) cells form in the lymph system): 1 person, 6.25%
Nausea And Vomiting: 1 person, 6.25%
Metastases To Bone (cancer spreads to bone): 1 person, 6.25%
Hyperlipidaemia (presence of excess lipids in the blood): 1 person, 6.25%
Hodgkin's Lymphoma (cancer originating from white blood cells): 1 person, 6.25%
Burkitt Lymphoma (cancer of the lymphatic system): 1 person, 6.25%
Blood Uric Acid Decreased: 1 person, 6.25%

* Approximation only. Some reports may have incomplete information.

Do you take Cyclophosphamide and have Hydrocele?

- Check whether Hydrocele is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Cyclophosphamide:

Cyclophosphamide (185,240 reports)

Hydrocele treatments and more:

Hydrocele (1,718 reports)

Browse all side effects of Cyclophosphamide:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Hydrocele:

Hydrocele (275 drugs)

Browse all the conditions that are associated with Hydrocele:

Hydrocele (388 conditions)

Related publications that referenced our studies

Hu P, Lu L, Hu B, Deng F, Fei WJ, "Cyclophosphamide‐Induced Hypertensive Encephalopathy in a Young Girl With Lupus", The Journal of Clinical Hypertension, 2012 Apr .
Hu P, Lu L, Hu B, Deng F, Fei WJ, "Cyclophosphamide‐Induced Hypertensive Encephalopathy in a Young Girl With Lupus", The Journal of Clinical Hypertension, 2012 Apr .

How the study uses the data?

The study uses data from the FDA. It is based on cyclophosphamide (the active ingredients of Cyclophosphamide) and Cyclophosphamide (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.